Atlas›Domain IX · Biomedical, neuro & digital›Guide 026
Guide IX-026

Cranial electrotherapy stimulation (contested)

1979USA
A 26 · L 67 · M 713 interventions in the Trinity explorer
Client cardCompare
[source: …] where a claim comes from[uncertain] not confirmed in a primary source[synthesis] the writer's reconstruction

1. Introduction

Version followed: the US FDA regulation for cranial electrotherapy stimulators (21 CFR 882.5800, as amended by FDA's final order of 20 December 2019); NICE health technology guidance HTG570 (formerly MTG56, published March 2021, migrated December 2025 with recommendations unchanged); one manufacturer's published labelling (Alpha-Stim) as an example of how labelling reads; evidence status from the 2018 VA Evidence Synthesis Program review, the 2014 Cochrane review and US Military Health System evidence briefs. Status checked October 2026.

Contested method. Cranial electrotherapy stimulation (CES) is a device treatment, not a psychotherapy. FDA defines the device as a prescription device that applies electrical current to a patient's head, not intended to induce a seizure, to treat psychiatric conditions [source: FDA final order 2019]. It is usually a small battery-powered unit that can be self-administered at home or used by a healthcare professional in a clinic [source: NICE HTG570]. Manufacturers claim benefit for anxiety, insomnia and (outside the US) depression; independent reviewers rate the evidence as low-strength or insufficient, and NICE does not recommend routine adoption. How it might work is not established: NICE's committee found the mechanism of action uncertain and existing EEG studies did not link brain-wave changes to symptom change [source: NICE HTG570]. There is therefore no agreed "core idea of how change happens"; claims about mechanism are the manufacturers' and should be presented as such.

This guide is written for the psychotherapist whose clients use, buy, or ask about CES devices, working alongside the prescriber or treating team. It gives no device settings, electrode placements, treatment schedules or protocol details; those are a matter for the device labelling and the prescriber. Who may order the device differs by jurisdiction (see the regulatory table below). [synthesis]

Regulatory status (checked October 2026)

  • United States, classification history. CES devices were first classified in 1979 as preamendment devices [source: FDA final order 2019]. FDA convened its Neurological Devices Panel on 10 February 2012, issued a proposed order on 22 January 2016 (over 300 comments received), and published a final order on 20 December 2019, effective that day [source: FDA final order 2019].
  • US, anxiety and/or insomnia: class II (special controls). Since December 2019, CES devices intended for anxiety and/or insomnia are class II and need 510(k) clearance; already marketed devices had until 21 December 2020 to file a 510(k) amendment showing compliance with the special controls [source: FDA final order 2019]. Special controls include labelling of the intended population, a warning that a physician should monitor patients for signs of worsening, instructions on reducing and responding to headaches and dizziness, and a summary of clinical testing and adverse events [source: FDA final order 2019].
  • US, depression: class III (premarket approval required). FDA kept CES for depression in class III, concluding that without an established positive benefit-risk profile it presents a "potential unreasonable risk of illness or injury"; FDA found no studies in a DSM-5 primary depressive disorder population and judged depression the weakest-evidenced of the three indications [source: FDA final order 2019]. A PMA or completed product development protocol had to be filed by 19 March 2020 for depression-intended devices already on the market; any other CES device with a depression indication needs an approved PMA before commercial distribution [source: Federal Register 84 FR 70013]. As of October 2026, a June 2025 US insurer medical policy lists only 510(k) clearances (most recently for anxiety and insomnia products in 2023–2024) and no PMA approval for depression [source: BCBS policy SUR702.019, 2025]; Alpha-Stim states its US devices are "FDA cleared for anxiety, insomnia and pain only" [source: Alpha-Stim indication and risk page]. The absence of any depression PMA is [uncertain].
  • US, prescription and ages. CES is a prescription device; FDA says it "may not be safe for use except under the authorization of a healthcare professional" [source: FDA final order 2019]. The order sets no age limits; labelling must state the intended population [source: FDA final order 2019]. Alpha-Stim's US labelling states use for people 18 or older and notes that long-term effects on the developing brain have not been studied [source: Alpha-Stim indication and risk page]. Which professions may order a CES device depends on state law and was not verified [uncertain].
  • Terminology. Some official sources call CES "FDA-approved" for depression on the basis of the 1979 classification and later "substantially equivalent" clearances [source: PHCoE 2020; PHCoE 2023]; FDA's 2019 order treats depression claims as requiring premarket approval. When talking with clients, say "cleared" for anxiety/insomnia devices and do not describe any device as approved for depression unless the prescriber confirms a PMA. [synthesis]
  • Europe. Alpha-Stim reports CE marking (class IIa) for anxiety, insomnia, depression and pain in adults aged 22 and over, and sale without prescription outside the US [source: Alpha-Stim indication and risk page; manufacturer's claim, not verified with a notified body or EU database] [uncertain].
  • United Kingdom (NICE). NICE HTG570 (Alpha-Stim AID for anxiety disorders) says the device "shows promise" but there is "not enough good-quality evidence to support the case for routine adoption"; it recommends research comparing it with individual CBT and/or medication, and studies of its effect on brain function [source: NICE HTG570]. NICE does not state the UK regulatory marking [uncertain].
  • Canada. Health Canada reportedly licensed one CES device in 2014 and issued an advertising enforcement letter in 2015 over marketing claims [source: Wikipedia, Fisher Wallace Laboratories] [uncertain].
  • US military and VA. The Psychological Health Center of Excellence concluded the evidence is "not mature enough to recommend CES as an evidence-based treatment" for MDD in the Military Health System and notes that the 2022 VA/DoD MDD guideline does not include CES [source: PHCoE 2023].
  • Payers. A US insurer policy (effective June 2025) classes CES as "experimental, investigational and/or unproven in all situations" and found no professional-society guidelines or statements on it [source: BCBS policy SUR702.019, 2025].

Evidence status (checked October 2026; contested)

  • VA Evidence Synthesis Program, February 2018 (Shekelle and colleagues): low-strength evidence of a possible modest benefit in patients with anxiety and depression combined; insufficient evidence for depression alone, anxiety alone, insomnia, headache and fibromyalgia; no randomised trials for PTSD; all included trials at high risk of bias, mainly from inadequate blinding; probably safe on low-strength evidence, with 16 of 26 trials reporting no safety data [source: VA ESP 2018]. The lead in some summaries calls this an "AHRQ" review; the version opened is the VA ESP report. A journal version exists [uncertain].
  • Cochrane, July 2014 (Kavirajan, Lueck, Chuang): no trials met inclusion criteria; "insufficient evidence to support the use of CES in treatment of acute depression" [source: Cochrane CD010521].
  • NICE, 2021: low-quality evidence, high risk of bias, concern about a placebo effect, mostly short studies so long-term benefit unknown, no comparison with CBT or medication [source: NICE HTG570].
  • Later studies (reported second-hand): the 2025 insurer policy summarises meta-analyses by Price et al. (2021) and Ching et al. (2022) reporting symptom reductions with heterogeneity and limitations, a 2023 randomised trial (Morriss et al., Alpha-Stim-D) finding no significant difference from sham for major depression, and a 2024 trial (Gehrman et al.) positive only in a high-adherence subgroup [source: BCBS policy SUR702.019, 2025] [uncertain].
  • Claims by manufacturers and advocates: manufacturers present CES as effective and low-risk; Alpha-Stim states adverse effects are rare, mild and self-limiting [source: Alpha-Stim indication and risk page]. Device makers publicly disputed FDA's handling of the 2012 panel and the 2016 proposal [source: Wikipedia, Fisher Wallace Laboratories] [uncertain].

Consumer-marketing warnings, as regulators give them

  • FDA treats CES as prescription-only because safe use requires a healthcare professional's authorisation [source: FDA final order 2019].
  • In the US, marketing a CES device for depression requires an approved PMA [source: Federal Register 84 FR 70013]. Online sellers' depression claims for US buyers should be checked with the prescriber. [synthesis]
  • FDA has acted on claims beyond a device's clearance: a 2004 class 2 recall of one CES device for implied claims ("extremes of compulsive or addictive behavior") outside the scope of its clearance, corrected by changing the user manual [source: FDA recall Z-0019-05].
  • FDA's post-2016 adverse event review included a third-degree burn when a device was used to "improve brain functioning", a use outside the cleared indications [source: FDA final order 2019].
  • NICE warns that the anxiety evidence may reflect a placebo effect and that no head-to-head evidence against CBT or medication exists [source: NICE HTG570].

2. Framework

CES has no psychotherapeutic phases. Course length and session schedules are set by the labelling and the prescriber and are not given here. Below is a framework for the psychotherapist's involvement, in four stages. [synthesis, built on the regulatory and labelling sources above]

  • Stage A: the client raises CES (one session segment, or more as needed). Goal: find out what the client knows, wants and is already doing; give balanced, attributed information; do not endorse. Move on when the client has the facts and knows the decision belongs with a prescriber.
  • Stage B: routing and shared decision-making (between sessions, with consent). Goal: the client discusses CES with the prescriber or GP/primary care clinician; with consent, the therapist shares relevant clinical observations. Move on when a prescriber has made a decision with the client, or the client has decided not to pursue it.
  • Stage C: during device use (each session, brief check). Goal: monitor for worsening, adverse effects and safety issues, as FDA's labelling requirement anticipates; pass concerns to the prescriber; keep evidence-based psychotherapy going. Move to D when use ends or a medical review is triggered.
  • Stage D: after use ends. Goal: review what the client attributes change to; consolidate psychological skills; watch for relapse; record the outcome.

Criteria for leaving the routine framework and contacting the prescriber promptly: worsening mood or anxiety, new suicidal thoughts, skin burns, persistent headache or dizziness, use with an implanted cardiac device, pregnancy, use by a child or adolescent, home-made or modified devices, or use while driving [source: FDA final order 2019; Alpha-Stim indication and risk page; NICE HTG570; synthesis for the grouping].

3. Guiding principles

  • Prescriber's decision, not the therapist's. Never advise starting, stopping or changing device use; route those questions to the prescriber [source: FDA final order 2019 for prescription status; synthesis].
  • Label it contested. Present CES as a contested treatment and attribute every efficacy claim ("the manufacturer says…", "NICE concluded…") [synthesis].
  • No endorsement and no commercial ties. Do not sell, rent, recommend brands, use affiliate links or display vendor material; disclose any relationship with a manufacturer [synthesis].
  • Accurate wording on status. Distinguish "cleared" (510(k), anxiety/insomnia) from "approved" (PMA); do not call CES approved for depression [source: FDA final order 2019; synthesis].
  • Evidence-based care stays in place. NICE notes no comparison with CBT; keep recommended psychological treatment going rather than substituting the device [source: NICE HTG570; synthesis].
  • Watch for worsening. FDA-required labelling warns that patients should be monitored for signs of worsening; ask about mood and anxiety at every contact while the device is used [source: FDA final order 2019].
  • Pass on, do not manage, adverse effects. Record and relay headaches, dizziness, skin irritation or burns, worsening anxiety or depression to the prescriber [source: FDA final order 2019; VA ESP 2018; NICE HTG570].
  • Respect autonomy. A client may choose to use a cleared device; your role is information, safety and collaboration, not persuasion [synthesis].
  • Stay within scope. Whether a psychotherapist may order a CES device in a given US state is a legal and licensing question; check with your licensing board and insurer before any involvement beyond discussion [uncertain; synthesis].
  • Say no to DIY. Do not help with home-built, modified or non-labelled stimulation; FDA lists electrical shocks and burns among the device risks [source: FDA final order 2019; Alpha-Stim indication and risk page].

4. Intervention inventory

Part A describes the device treatment as regulators and labelling describe it, at a descriptive level only. Part B gives the psychotherapist's own interventions. All example language is illustrative.

A1. How CES is delivered (descriptive, from official sources)

  • Purpose: to give you an accurate picture so you can answer client questions without guessing or endorsing.
  • What sources say: a portable, battery-powered device about the size of a mobile phone, with adjustable strength, that passes low-intensity current to the head through electrodes; used at home by the patient or in a hospital or clinic [source: NICE HTG570]. In the US it is a prescription device ordered by a licensed practitioner and self-administered [source: FDA final order 2019; PHCoE 2023]. The labelling, which by FDA rule must base its instructions on clinical study results, sets how and how often it is used [source: FDA final order 2019]. Settings, electrode placement and schedules are deliberately not described here.
  • Contraindications and cautions (as labelling gives them): contraindicated with implanted pacemakers and implanted or wearable defibrillators; safety in pregnancy not established; do not drive or operate dangerous machinery during treatment and in some cases for hours afterwards; physician monitoring for signs of worsening; consult a physician if headaches occur; not for children in the US labelling (18 and over) [source: Alpha-Stim indication and risk page; NICE HTG570].
  • Adverse effects (as sources report): FDA lists ineffective treatment, skin irritation, headaches, dizziness, electrical shocks and burns [source: FDA final order 2019]; the VA review found tingling or skin irritation, tiredness or sleepiness and possibly transient visual symptoms more often with active CES, and one early study reported worsened depression in four patients, two hospitalised, not replicated [source: VA ESP 2018]; NICE reports mild headache, dizziness, nausea and feeling strange, and in a patient survey ear discomfort and worsening anxiety [source: NICE HTG570].
  • Watch for: clients describing settings or placements they invented or found online, use for unlisted purposes ("brain enhancement"), or devices bought from unverified sellers; all go to the prescriber [synthesis].
  • Example language (illustrative): "It's a small prescription device that passes a weak current to the head. How and how often it's used is set by the labelling and your prescriber, not by me." [synthesis]

B1. Responding when a client asks about CES

  • Purpose: give balanced, attributed information and route the decision to a prescriber, without endorsing or dismissing.
  • When: a client mentions an advert, a friend's device, or asks "Should I try one?"
  • Steps:
    1. Ask what they have heard, where (advert, social media, clinician), and what they hope it will do.
    2. Ask what they are currently doing for the problem (psychotherapy, medication, sleep interventions).
    3. Say plainly that CES is a device treatment outside your role, and that its benefits are contested.
    4. Give the status in brief: in the US, cleared for anxiety and insomnia as a prescription device, not approved for depression; NICE in England does not recommend routine use for anxiety; reviews rate the evidence low or insufficient (section 1 above).
    5. Name the safety screens the prescriber will consider (heart devices, pregnancy, driving, age) without assessing them yourself.
    6. Suggest they discuss it with their prescriber or primary care clinician; offer, with consent, to share your clinical picture.
    7. Return to the psychological work and agree how you will track symptoms whatever they decide.
    8. Record the conversation and what information you gave.
  • Example language (illustrative): "Devices like this are a medical treatment, so the decision sits with your doctor, not me. What I can tell you is what the regulators and reviewers have said, and that's mixed." / "The company says it helps anxiety. The reviews I've seen say the evidence is weak and may partly reflect expectation. Your doctor can go through whether it's right for you."
  • Watch for: hope that the device replaces harder therapeutic work; urgency driven by marketing; signs the client is already using it. It is working when the client can describe the status accurately and has a plan to talk to a prescriber. [synthesis]

B2. Responding when a client already uses a device

  • Purpose: bring device use into the clinical picture safely and connect it to the prescriber.
  • Steps:
    1. Ask neutrally: which device, how obtained (prescribed, bought online, abroad), for what problem, since when, and whether the prescriber knows.
    2. Ask about effects, good and bad, including headaches, dizziness, skin irritation or burns, sleepiness, and any change in mood or anxiety.
    3. Ask about the safety screens on the labelling: implanted heart device, pregnancy, driving soon after use, use by a young person in the household.
    4. If not prescribed or the prescriber is unaware, encourage the client to tell the prescriber; do not tell them to stop.
    5. If any red flag appears (section 2 criteria), ask consent to contact the prescriber the same day, or advise urgent medical care if severe.
    6. Agree to check in briefly each session (B6).
  • Example language (illustrative): "Thanks for telling me. I'm not going to tell you to stop or carry on; that's for your doctor. Does your doctor know you're using it?" / "Have you noticed headaches, dizziness or any skin marks where it touches you?"
  • Watch for: shame or secrecy; modified or home-made units (B9). Working when device use is known to the prescriber and tracked. [synthesis]

B3. Psychoeducation on status and evidence

  • Purpose: help clients weigh marketing against independent assessment.
  • Steps:
    1. Separate three things: what the regulator allows (cleared for which conditions), what independent reviewers concluded, and what the seller claims.
    2. Explain "cleared" versus "approved" in plain words (section 1, Terminology).
    3. Mention placebo concerns and short trial follow-up as NICE describes them [source: NICE HTG570].
    4. Note that it has not been compared with CBT or medication [source: NICE HTG570].
    5. Give the date you checked and say status can change; the prescriber can confirm the current label.
  • Example language (illustrative): "Being cleared by the FDA for anxiety means it can be legally sold on prescription for that use. It doesn't mean it's been shown to work as well as therapy or medication; nobody has tested that head to head."
  • Watch for: the client hearing "cleared" as "proven", or your own tone tipping into dismissal. [synthesis]

B4. Supporting informed consent and shared decision-making

  • Purpose: help the client go into the prescriber conversation prepared.
  • Steps:
    1. Help the client write down their questions, for example: Is this device cleared for my condition where I live? What does the evidence show for people like me? What side effects should I report? Does anything about my health rule it out? How will we know whether it's helping, and when will we review it? What does it cost and is it covered?
    2. Clarify the client's values and priorities (cost, time, side effects, wish to avoid or reduce medication).
    3. With consent, send the prescriber a brief summary: diagnosis, current psychological treatment, symptom measures, risk.
    4. After the appointment, review what was decided and how it fits the therapy plan.
  • Example language (illustrative): "Let's make a short list of questions so you get what you need from the appointment."
  • Watch for: pressure from the client to have you "sign off" the device; decline and route. [synthesis]

B5. Recognising when to suggest a medical review

  • Purpose: timely prescriber or urgent medical involvement.
  • Triggers: worsening depression or anxiety (FDA labelling requires a worsening warning) [source: FDA final order 2019]; new or increased suicidal thinking; burns or persistent skin damage; persistent headache or dizziness [source: FDA final order 2019]; implanted pacemaker or defibrillator, pregnancy [source: Alpha-Stim indication and risk page; NICE HTG570]; use by under-18s; home-made or modified devices; use for depression without prescriber involvement; any fall, accident or near-miss while driving after use [synthesis for grouping].
  • Steps: name the concern, seek consent to contact the prescriber, make the contact, document; if the client declines and risk is significant, follow your service's risk and confidentiality policy.
  • Example language (illustrative): "What you're describing is something your doctor needs to know about this week. Can I let them know, or would you rather call them today?"
  • Watch for: delays because the client fears being told to stop. [synthesis]

B6. Monitoring and passing on adverse effects

  • Purpose: a reliable channel from what the client tells you to the prescriber, matching the labelling's call for monitoring of worsening.
  • Steps:
    1. Each session while the device is in use, ask two or three brief questions: mood and anxiety compared with last week, sleep, any headaches, dizziness, skin irritation, burns, or other new effects [source for effects: FDA final order 2019; VA ESP 2018; NICE HTG570].
    2. Keep using your usual standardised symptom measures so change is tracked the same way before, during and after.
    3. Record effects in the client's words, with dates.
    4. Pass on anything new or worsening to the prescriber with consent; urgent concerns the same day.
    5. Suggest the client or prescriber reports serious device problems to the national regulator's adverse event scheme (for example FDA MedWatch in the US or the MHRA Yellow Card scheme in the UK) [synthesis] [uncertain].
  • Example language (illustrative): "Quick device check: any headaches, dizziness or skin soreness since last time? And how has your mood been compared with before you started?"
  • Watch for: worsening anxiety, which NICE's patient survey recorded [source: NICE HTG570], and worsened depression, reported in one early study [source: VA ESP 2018]. It is working when the prescriber hears about effects promptly and the record is clear. [synthesis]

B7. Conversations about adherence and ambivalence

  • Purpose: help the client explore mixed feelings about the device without advising any change.
  • Steps:
    1. Reflect both sides (hope for relief; doubts, cost, side effects, inconvenience).
    2. Ask what the client has noticed, and what they think it means.
    3. If they want to stop, start, use it differently, or follow advice from a seller or forum, route the question to the prescriber.
    4. Note that changes in symptoms may have many causes (therapy, life events, expectation) and that you will keep measuring either way.
  • Example language (illustrative): "It sounds like part of you wants to keep going and part of you isn't sure it's doing anything. That's a good thing to take to your doctor, along with the scores we've been keeping."
  • Watch for: the client changing use by themselves after an online tip; reliance on the device as a way of avoiding feared situations (B10). [synthesis]

B8. Crisis and safety planning

  • Purpose: ensure the device never stands in for a safety plan.
  • Steps:
    1. For clients with depression or suicidal thinking, keep a current written safety plan using your service's standard approach (warning signs, coping steps, people and places, professional and emergency contacts, reducing access to lethal means).
    2. Make clear the device is not a crisis tool and is not approved in the US for depression [source: FDA final order 2019].
    3. Any increase in suicidal thinking while using a device triggers a standard risk assessment and prescriber contact.
    4. Add "tell my doctor about any worsening" to the plan, reflecting the labelling's worsening warning [source: FDA final order 2019].
  • Example language (illustrative): "Whatever you decide about the device, let's make sure your safety plan is up to date, because it isn't something to rely on in a crisis."
  • Watch for: the client describing the device as their main coping strategy for suicidal urges. [synthesis]

B9. Responding to marketing claims, DIY stimulation and use by young people

  • Purpose: reduce harm from unlabelled use and misleading claims.
  • Steps:
    1. If a client shows an advert, read the claims with them and sort them into regulator-checked statements and seller claims (B3).
    2. If a seller claims a CES device treats depression for US buyers, note that FDA requires an approved PMA for that claim [source: Federal Register 84 FR 70013]; suggest the client checks with the prescriber.
    3. If the client is building, modifying or using an improvised stimulator, or using one for "brain enhancement", say clearly that you cannot support it and explain that FDA lists electrical shocks and burns among the risks and has a report of a third-degree burn from use to improve brain functioning [source: FDA final order 2019]; the manufacturer warns that modifying devices or plugging leads into mains sockets can cause injury, severe shock or burns [source: Alpha-Stim indication and risk page]. Do not discuss how to do it. Encourage medical review.
    4. For a child or adolescent client, or a parent asking about a child: US labelling for one device restricts use to people 18 or older and notes unstudied long-term effects on the developing brain [source: Alpha-Stim indication and risk page]; route to the child's physician.
  • Example language (illustrative): "I can't help with setting up a home-made stimulator; the regulator has reports of shocks and burns. What I can do is help you get a proper medical opinion."
  • Watch for: secrecy, especially in adolescents; online communities sharing settings. [synthesis]

B10. Integrating psychotherapy before, during and after device use

  • Purpose: keep evidence-based psychological treatment central and avoid the device undermining it.
  • Steps:
    1. Before: confirm the formulation and the recommended psychological treatment for the problem (for anxiety disorders in England, NICE's stepped care including CBT [source: NICE HTG570]).
    2. During: continue the agreed therapy; keep measuring outcomes; watch whether device use is becoming a safety or avoidance behaviour (for example, using it to escape exposure tasks) and discuss this openly; route any question about use itself to the prescriber.
    3. Help the client attribute gains to their own skills where that fits, so improvement is not tied to the device alone.
    4. After: review gains, consolidate a relapse-prevention plan, and record what changed.
  • Example language (illustrative): "Whatever the device is doing, the skills you're practising here are yours. Let's look at which ones you used this week."
  • Watch for: reduced engagement in therapy; dismissal of psychological work as unnecessary. [synthesis]

B11. Support after device use ends

  • Purpose: prevent relapse and disappointment from derailing care.
  • Steps: ask how the decision to stop was made (with the prescriber or not); check mood, anxiety and sleep over the following weeks; normalise disappointment if it did not help; revisit the treatment plan and whether a medical review of other options is needed; pass any return of symptoms to the prescriber.
  • Example language (illustrative): "You'd hoped this would help more than it did. That's disappointing, and it doesn't mean nothing will. Let's look at what's next with your doctor."
  • Watch for: hopelessness after a "failed" treatment; symptom return. [synthesis]

B12. Your own professional position

  • Purpose: avoid endorsement, conflicts of interest and practice outside scope.
  • Steps:
    1. Decline vendor offers (free devices, referral fees, affiliate schemes, displaying brochures) or seek ethics advice before any involvement.
    2. Before any role in ordering or supplying a device, check your licensing board, scope-of-practice law and liability insurer; prescription status in the US is set by FDA [source: FDA final order 2019], but who may order is a state matter [uncertain].
    3. Document what information you gave, with sources and the date checked.
    4. Keep your knowledge current: status and evidence change, so recheck before relying on this guide.
  • Watch for: drifting from information into recommendation. [synthesis]
  • Example language (illustrative): "I don't sell or recommend devices and I have no links with any manufacturer, so what I say about them stays independent of your therapy." [synthesis]

5. Handling problems

The official sources give no guidance on psychotherapy process issues; all responses below are [synthesis] unless a source is named.

  • Client wants you to endorse or "approve" the device. Decline warmly, explain that the decision belongs with a prescriber, give the attributed status, and offer to help prepare questions (B4). "I'm not the right person to say yes or no to it, but I can help you get a clear answer from someone who is." (illustrative)
  • Client is angry that you seem sceptical. Acknowledge the hope behind the interest; separate your role (information and safety) from a verdict; show that you are quoting regulators and reviewers, not your opinion; keep the alliance focused on shared goals. Repair if you sounded dismissive.
  • Client believes the device is proven because it is "FDA cleared". Explain clearance in plain words (B3); point out that FDA itself kept depression in the highest-risk class because benefit had not been shown [source: FDA final order 2019].
  • Client uses the device for depression in the US without a prescriber. Do not tell them to stop; explain that depression is not a cleared US indication and that the labelling expects physician monitoring for worsening [source: FDA final order 2019]; encourage prescriber contact; increase symptom and risk monitoring.
  • Worsening mood or anxiety during use. Treat as a red flag: risk assessment, safety plan review, prescriber contact the same day for significant change. Worsening anxiety and worsened depression have been reported [source: NICE HTG570; VA ESP 2018].
  • Burns, skin damage, persistent headache or dizziness. Advise the client to seek medical advice and inform the prescriber; these are listed risks [source: FDA final order 2019; Alpha-Stim indication and risk page].
  • Client has a pacemaker or defibrillator, or is pregnant. These are labelled contraindication or caution areas [source: Alpha-Stim indication and risk page; NICE HTG570]; prescriber contact before any further use is their decision with the client; you pass on the information.
  • Driving after use. Labelling warns against driving or operating dangerous machinery during and for some hours after treatment [source: Alpha-Stim indication and risk page; NICE HTG570]; remind the client and include this in any safety discussion.
  • Device becomes avoidance. If the client uses the device to escape anxiety rather than approach feared situations, discuss its function openly, as you would any safety behaviour, and keep exposure work going with the usual consent and pacing; leave the device decision to the prescriber.
  • Stuck therapy because the client is waiting for the device to work. Agree a review point with the prescriber; meanwhile name what therapy can do now; use measures to show where things stand.
  • Non-adherence to therapy homework while device use continues. Explore beliefs ("the machine will fix it"); link homework to the client's own goals; avoid framing the device as competition.
  • Overwhelm or disappointment when the device does not help. Normalise, review options with the prescriber, guard against hopelessness (B11), check risk.
  • Teenager using a parent's or friend's device. Engage the parent or guardian as your confidentiality rules allow; US labelling for one device is 18 and over [source: Alpha-Stim indication and risk page]; route to the young person's physician.
  • Client shares DIY instructions or asks you to review settings. Decline to discuss them; describe the documented risks (shocks, burns) [source: FDA final order 2019]; encourage medical review (B9).
  • Conflicting sources on status. Some official military briefs say "FDA-approved" for depression [source: PHCoE 2023] while FDA's 2019 order requires premarket approval for depression; give the client FDA's wording and ask the prescriber to confirm the device's current label.
  • Vendor or colleague pressure to offer CES in your practice. Seek ethics and legal advice; check scope of practice and insurance; avoid financial ties (B12).
  • Rupture after routing to the prescriber (client feels passed on). Explain that routing is about safety, not rejection; stay involved in the psychological work; follow up on what happened.

Sources

← Previous · IX-025Supraorbital and sphenopalatine-ganglion stimulationNext · IX-027 →Photobiomodulation